Abstract: Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis.

Abstract: Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis.

Abstract: Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis.

Abstract: Synthetic unaltered and altered peptides comprising sequences of at least one immunogenic epitope cluster (IEC) of at least one human autoantigen related to multiple sclerosis (MS) and at least one nonameric core sequence which fits into the MS-relevant HLA-DR/DQ molecule and is flanked by 2-5 amino acids at its N- and C-termini, are provided. The alteration is preferably by substituting 1 to 3 TCR contact residues by Ala. The autoantigen is preferably MOG, MBP, OSP, MOBP and PLP. Polypeptides comprising at least two such peptides of a sole autoantigen or at least one peptide of two different autoantigens, and synthetic genes encoding them, are also provided, as well as pharmaceutical compositions for treatment and diagnostic of MS.

Abstract: Synthetic unaltered and altered peptides comprising sequences of at least one immunogenic epitope cluster (IEC) of at least one human autoantigen related to multiple sclerosis (MS) and at least one nonameric core sequence which fits into the MS-relevant HLA-DR/DQ molecule and is flanked by 2-5 amino acids at its N- and C-termini, are provided. The alteration is preferably by substituting 1 to 3 TCR contact residues by Ala. The autoantigen is preferably MOG, MBP, OSP, MOBP and PLP. Polypeptides comprising at least two such peptides of a sole autoantigen or at least one peptide of two different autoantigens, and synthetic genes encoding them, are also provided, as well as pharmaceutical compositions for treatment and diagnostic of MS.